APA

Merat S. J., Bru C., van de Berg D., Molenkamp R., Tarr A. W., Koekkoek S., Kootstra N. A., Prins M., Ball J. K., Bakker A. Q., de Jong M. D., Spits H., Beaumont T. & Schinkel J. (20201214). Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. : Journal of hepatology.

Chicago

Merat Sabrina J, Bru Camille, van de Berg Dorien, Molenkamp Richard, Tarr Alexander W, Koekkoek Sylvie, Kootstra Neeltje A, Prins Maria, Ball Jonathan K, Bakker Arjen Q, de Jong Menno D, Spits Hergen, Beaumont Tim and Schinkel Janke. 20201214. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. : Journal of hepatology.

Harvard

Merat S. J., Bru C., van de Berg D., Molenkamp R., Tarr A. W., Koekkoek S., Kootstra N. A., Prins M., Ball J. K., Bakker A. Q., de Jong M. D., Spits H., Beaumont T. and Schinkel J. (20201214). Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. : Journal of hepatology.

MLA

Merat Sabrina J, Bru Camille, van de Berg Dorien, Molenkamp Richard, Tarr Alexander W, Koekkoek Sylvie, Kootstra Neeltje A, Prins Maria, Ball Jonathan K, Bakker Arjen Q, de Jong Menno D, Spits Hergen, Beaumont Tim and Schinkel Janke. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. : Journal of hepatology. 20201214.